P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL

P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL

Bibliographic Details
Main Authors:	Hanny Al-Samkari, Rachael F. Grace, Andreas Glenthøj, Wilma Barcellini, Madeleine Verhovsek, Jennifer A. Rothman, Marta Morado, Mark Layton, Oliver Andres, Frédéric Galactéros, Koichi Onodera, Satheesh Chonat, Rengyi Xu, Bryan Mcgee, Melissa Dibacco, Jaime Morales, Eduard van Beers
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972776.91875.6f

Similar Items

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
by: Eduard van Beers, et al.
Published: (2023-08-01)

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY
by: R. F. Grace, et al.
Published: (2022-06-01)

P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
by: W. Barcellini, et al.
Published: (2022-06-01)

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
by: Rachael F. Grace, et al.
Published: (2023-08-01)

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT
by: H. Al-Samkari, et al.
Published: (2022-06-01)

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
by: E. J. van Beers, et al.
Published: (2022-06-01)

P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
by: K. H. Kuo, et al.
Published: (2022-06-01)

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K Kuo, et al.
Published: (2022-01-01)

P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K. H. M. Kuo, et al.
Published: (2022-06-01)

P1543: MITAPIVAT DECREASES THE NEED FOR TRANSFUSIONS SECONDARY TO POORLY TOLERATED ANEMIA AND ACUTE EVENTS COMPARED TO PLACEBO IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
by: H. Al-Samkari, et al.
Published: (2022-06-01)

P1547: ACTIVATE-KIDS: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
by: R. F. Grace, et al.
Published: (2022-06-01)

P1546: ACTIVATE-KIDST: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
by: R. F. Grace, et al.
Published: (2022-06-01)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
by: Myrthe van Dijk, et al.
Published: (2023-08-01)

Mortality among US veterans with a physician-documented diagnosis of pyruvate kinase deficiency
by: Erin Zagadailov, et al.
Published: (2024-12-01)

P1479: COMORBIDITIES AND COMPLICATIONS IN ADULTS WITH PYRUVATE KINASE DEFICIENCY ACCORDING TO HEMOGLOBIN STRATA – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY
by: Dagmar Pospíŝilová, et al.
Published: (2023-08-01)

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: VAN DIJK M., et al.
Published: (2022-08-01)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: M.J. van Dijk, et al.
Published: (2023-04-01)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: M. J. van Dijk, et al.
Published: (2022-06-01)

ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: KH Kuo, et al.
Published: (2021-10-01)

P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K Kuo, et al.
Published: (2022-01-01)

14.73 The Challenge of World Poverty, Fall 2009
by: Donaldson, Dave, et al.
Published: (2009)

Interdiffusivity in titanium-tantalum alloys processed at 1473 K
by: Dibbern, Jennifer C
Published: (2009)

S273: EVIDENCE OF NONINFERIORITY OF MITAPIVAT VERSUS SPLENECTOMY IN MURINE HEREDITARY SPHEROCYTOSIS
by: A. Matte’, et al.
Published: (2022-06-01)

The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design
by: Yan Yan, et al.
Published: (2023-03-01)

P107: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN PATIENTS WITH SICKLE CELL DISEASE
by: J Howard, et al.
Published: (2022-01-01)

Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis
by: Alessandro Matte, et al.
Published: (2023-10-01)

P1562: CHARACTERIZING IRON OVERLOAD BY AGE IN PATIENTS DIAGNOSED WITH PYRUVATE KINASE DEFICIENCY – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY
by: P. Bianchi, et al.
Published: (2022-06-01)

Pyruvate Kinase Deficiency: Current Challenges and Future Prospects
by: Fattizzo B, et al.
Published: (2022-09-01)

P1542: COMORBIDITIES AND COMPLICATIONS ACROSS GENOTYPES IN ADULT PATIENTS WITH PYRUVATE KINASE DEFICIENCY: ANALYSIS FROM THE PEAK REGISTRY
by: A. Glenthøj, et al.
Published: (2022-06-01)

Experimental Investigation on Isothermal Sections at 1273 and 1473 K in the Co–Ti–W System
by: Yu Shi, et al.
Published: (2022-05-01)

Oxide particle coarsening at temperature over 1473K in 9CrODS steel
by: N. Oono, et al.
Published: (2016-12-01)

Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency
by: Anna Zaninoni, et al.
Published: (2023-03-01)

Investigation on occupational hazards and management status of 1473 manufacturing enterprises in Pudong New Area, Shanghai
by: XU Tiantian
Published: (2023-10-01)

PB2247: PHARMACOKINETIC MODELING AND SIMULATION TO SUPPORT MITAPIVAT DOSE SELECTION USED IN PEDIATRIC PHASE III STUDIES
by: O. Yin, et al.
Published: (2022-06-01)

An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivat
by: Chandra Prakash, et al.
Published: (2023-10-01)

The role of romiplostim for pediatric patients with immune thrombocytopenia
by: Hanny Al-Samkari, et al.
Published: (2020-04-01)

14.73x The Challenges of Global Poverty MITx on edX Course Report - 2013 Spring
by: Seaton, Daniel Thomas, et al.
Published: (2015)

El paper dels primers editors (1473-1523) en la fixació del català modern
Published: (2015-06-01)

PB2345: ADAPTING PATIENT EDUCATIONAL APPROACHES IN PYRUVATE KINASE DEFICIENCY: EUROPE AND NORTH AMERICA FINDINGS FROM THE AAC PATIENT AND CAREGIVER SURVEY
by: W. Barcellini, et al.
Published: (2022-06-01)

P1473: CREATING A RANDOM FOREST CLASSIFIER TO PREDICT HBF LEVELS IN SICKLE CELL DISEASE PATIENTS
by: C. Rakhit, et al.
Published: (2022-06-01)